The Biologics CDMO Market size is estimated at USD 15.32 billion in 2024, and is expected to reach USD 27.94 billion by 2029, growing at a CAGR of 12.78% during the forecast period (2024-2029).
With an increasing number of companies within the pharmaceutical sector considering outsourcing services, the demand for services from contract manufacturing and contract development manufacturing organizations will rise.
The biologics contract development and manufacturing organization (CDMO) market is highly concentrated, with close to half of the market being dominated by a few players. In 2021, major players, such as Catalent, Boehringer Ingelheim Group, Lonza Group, and Samsung Biologics, together accounted for more than 30.1% of the market studied.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook